The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Khakimova M.B.

Chazov National Medical Research Center of Cardiology

Komarov A.L.

National Medical Research Center of Cardiology named after academician E.I. Chazov

Dobrovolskiy A.B.

Chazov National Medical Research Center of Cardiology

Panchenko E.P.

National Medical Research Center of Cardiology

Personalized antiplatelet therapy in patients with coronary artery disease: past, present and future

Authors:

Khakimova M.B., Komarov A.L., Dobrovolskiy A.B., Panchenko E.P.

More about the authors

Journal: Russian Cardiology Bulletin. 2022;17(4): 5‑15

DOI: 10.17116/Cardiobulletin2022170415

Read: 2636 times

Download PDF (RU)
Contact the author
Table of contents

PERSONALIZED ANTIPLATELET THERAPY IN PATIENTS WITH CORONARY ARTERY DISEASE: PAST, PRESENT AND FUTURE
PERSONALIZED ANTIPLATELET THERAPY IN PATIENTS WITH CORONARY ARTERY DISEASE: PAST, PRESENT AND FUTURE

To cite this article:

Khakimova MB, Komarov AL, Dobrovolskiy AB, Panchenko EP. Personalized antiplatelet therapy in patients with coronary artery disease: past, present and future. Russian Cardiology Bulletin. 2022;17(4):5‑15. (In Russ.)
https://doi.org/10.17116/Cardiobulletin2022170415

Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Endo­vascular correction of lesions of coro­nary arte­ries and coro­nary artery bypass grafts in patients with coro­nary artery disease with recu­rrent ischemia after surgical myocardial reva­scularization. Russian Cardiology Bulletin. 2024;(4):34-40
Impact of different forms of outpatient follow-up on survival after acute coro­nary syndrome. Russian Cardiology Bulletin. 2024;(4-2):172-181
Refralon for drug-induced cardioversion of atrial fibrillation in patients with coro­nary artery disease. Russian Cardiology Bulletin. 2024;(4-2):188-196
Cost-effectiveness of using rubi­dium-82 chlo­ride perfusion PET for planning myocardial reva­scularization procedures. Piro­gov Russian Journal of Surgery. 2024;(12-2):58-65
Mode­rate ischemic mitral insu­fficiency with severe left ventricular dysfunction: surgical treatment depe­nding on predictors of adve­rse long-term outcomes. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(6):651-659
Radionuclide methods in analysis of myocardial perfusion and meta­bolic acti­vity. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(4):12-19
Reclassification of ischemic heart disease epidemiological criteria. Russian Journal of Preventive Medi­cine. 2024;(12):61-68
Effe­ctiveness of the second stage program of medi­cal reha­bilitation of patients with ischemic heart disease. Russian Journal of Preventive Medi­cine. 2024;(12):75-80
Pecu­liarities of placental microRNA expression in patients with preeclampsia and fetal growth restriction. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):14-25
A challenge of the embryo sele­ction: PGT-A-based diagnostics or prediction using an arti­ficial inte­lligece and time-lapse technology?. Russian Journal of Human Reproduction. 2024;(6):99-107
Abstract:

Dual-antiplatelet therapy (DAPT) with aspirin and P2Y12-receptor inhibitor is a standard treatment for patients undergoing percutaneous coronary intervention (PCI). History of personalized antiplatelet therapy based on platelet function testing or genetic testing allows choosing individual treatment schemes involving escalation and de-escalation especially in patients with high risk of thrombotic events (recent acute coronary syndrome). In recent years, short-term DAPT under control of residual platelet reactivity has become important after PCI in patients with high risk of hemorrhagic complications. This approach reduces the incidence of hemorrhagic events. The authors present evolution of approaches to personalized therapy and position of international experts.

Keywords:

platelet reactivity
percutaneous coronary intervention
genetic testing
acute coronary syndrome
bleeding events
antiplatelet therapy
coronary artery disease
thrombotic events
micro-RNA

Authors:

Khakimova M.B.

Chazov National Medical Research Center of Cardiology

Komarov A.L.

National Medical Research Center of Cardiology named after academician E.I. Chazov

Dobrovolskiy A.B.

Chazov National Medical Research Center of Cardiology

Panchenko E.P.

National Medical Research Center of Cardiology

Received:

26.09.2022

Accepted:

05.10.2022

Close metadata

References:

  1. Gurbel P, Bliden K, Hiatt B, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107(23):2908-2913. https://doi.org/10.1161/01.CIR.0000072771.11429.83
  2. Mega J, Simon T, Collet J, Anderson J, Antman E, Bliden K, Cannon C, Danchin N, Giusti B, Gurbel P, Horne B, Hulot J, Kastrati A, Montalescot G, Neumann F, Shen L, Sibbing D, Steg P, Trenk D, Wiviott S, Sabatine M. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821-1830. https://doi.org/10.1001/jama.2010.1543
  3. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dörrler K, Morath T, Schömig A, Kastrati A, von Beckerath N. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. European Heart Journal. 2009;30(8):916-922.  https://doi.org/10.1093/eurheartj/ehp041
  4. Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, Golanski J, Sitkiewicz D, Pregowski J, Gorski J, Zembala M, Opolski G, Huber K, Arnesen H, Kristensen S, De Caterina R. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal. 2009;30(4):426-435.  https://doi.org/10.1093/eurheartj/ehn562
  5. Roberts J, Wells G, Le May M, Labinaz M, Glover C, Froeschl M, Dick A, Marquis J, O’Brien E, Goncalves S, Druce I, Stewart A, Gollob M, So D. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet. 2012;379(9827):1705-1711. https://doi.org/10.1016/S0140-6736(12)60161-5
  6. Agewall S, Cattaneo M, Collet J, Andreotti F, Lip G, Verheugt F, Huber K, Grove E, Morais J, Husted S, Wassmann S, Rosano G, Atar D, Pathak A, Kjeldsen K, Storey R; ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. European Heart Journal. 2013;34:1708-1713. https://doi.org/10.1093/eurheartj/eht042
  7. Levine G, Jeong Y, Goto S, Anderson J, Huo Y, Mega J, Taubert K, Smith S Jr. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nature Reviews Cardiology. 2014;11(10):597-606.  https://doi.org/10.1038/nrcardio.2014.104
  8. Price M, Berger P, Teirstein P, Tanguay J, Angiolillo D, Spriggs D, Puri S, Robbins M, Garratt K, Bertrand O, Stillabower M, Aragon J, Kandzari D, Stinis C, Lee M, Manoukian S, Cannon C, Schork N, Topol E; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 305(11):1097-1105. https://doi.org/10.1001/jama.2011.290
  9. Collet J, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Boueri Z, Belle L, Van Belle E, Rousseau H, Aubry P, Monségu J, Sabouret P, O’Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthélémy O, Beygui F, Silvain J, Vicaut E, Montalescot G; ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. The New England Journal of Medicine. 2012;367(22):2100-2109. https://doi.org/10.1056/NEJMoa1209979
  10. Trenk D, Stone G, Gawaz M, Kastrati A, Angiolillo D, Müller U, Richardt G, Jakubowski J, Neumann F. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. Journal of the American College of Cardiology. 2012;59(24):2159-2164. https://doi.org/10.1016/j.jacc.2012.02.026
  11. Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C, Delarche N, Bellemain-Appaix A, Range G, El Mahmoud R, Carrié D, Belle L, Souteyrand G, Aubry P, Sabouret P, du Fretay X, Beygui F, Bonnet J, Lattuca B, Pouillot C, Varenne O, Boueri Z, Van Belle E, Henry P, Motreff P, Elhadad S, Salem J, Abtan J, Rousseau H, Collet J, Vicaut E, Montalescot G; ANTARCTIC investigators. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 2016;388(10055):2015-2022. https://doi.org/10.1016/S0140-6736(16)31323-X
  12. Sibbing D, Gross L, Trenk D, Jacobshagen C, Geisler T, Hadamitzky M, Merkely B, Kiss R, Komócsi A, Parma R, Felix S, Neumann F, Hausleiter J, Baylacher M, Koltowski L, Mehilli J, Huber K, Huczek Z, Aradi D, Massberg S; TROPICAL-ACS Investigators. Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial. European Heart Journal. 2018;39(29):2749-2758. https://doi.org/10.1093/eurheartj/ehy332
  13. Siller-Matula J, Francesconi M, Dechant C, Jilma B, Maurer G, Delle-Karth G, Gouya G, Ruzicka K, Podczeck-Schweighofer A, Christ G. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. International Journal of Cardiology. 2013;167(5):2018-2023. https://doi.org/10.1016/j.ijcard.2012.05.040
  14. Mayer K, Schulz S, Bernlochner I, Morath T, Braun S, Hausleiter J, Massberg S, Schunkert H, Laugwitz K, Kastrati A, Sibbing D. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. The Journal of Thrombosis and Haemostasis. 2014;112(2):342-3451. https://doi.org/10.1160/TH13-10-0874
  15. Aradi D, Tornyos A, Pintér T, Vorobcsuk A, Kónyi A, Faluközy J, Veress G, Magyari B, Horváth I, Komócsi A. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. Journal of the American College of Cardiology. 2014;63(11):1061-1070. https://doi.org/10.1016/j.jacc.2013.12.023
  16. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni M, Barragan P, Dignat-George F, Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. Journal of the American College of Cardiology. 2008;51(14):1404-1411. https://doi.org/10.1016/j.jacc.2007.12.044
  17. Wang X, Zhang D, Zhuang S, Lai Y. Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. Clinical Cardiology. 2011;34(5):332-338.  https://doi.org/10.1002/clc.20884
  18. Antman E, Wiviott S, Murphy S, Voitk J, Hasin Y, Widimsky P, Chandna H, Macias W, McCabe C, Braunwald E. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Journal of the American College of Cardiology. 2008;51(21):2028-2033. https://doi.org/10.1016/j.jacc.2008.04.002
  19. Tang Y, Wang W, Yang M, Zhang K, Chen J, Qiao S, Yan H, Wu Y, Huang X, Xu B, Gao R, Yang Y; CREATIVE Investigators. Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial. Circulation. 2018;137(21):2231-2245. https://doi.org/10.1161/CIRCULATIONAHA.117.030190
  20. Montalescot G, Bavry A, Bhatt D. Assessment of a Normal versus Tailored dose of prasugrel after stenting in patients Aged >75 years to Reduce the Composite of bleeding, stent Thrombosis, and Ischemic Complications — ANTARCTIC European Society of Cardiology Congress. 2016. https://www.escardio.org/The-ESC/Press-Office/Press-releases/antarctic-trial-antiplatelet-monitoring-no-benefit-in-elderly-patients
  21. Sousa-Uva M, Head J, Milojevic M, Collet J, Landoni G, Castella M, Dunning J, Gudbjartsson T, Linker N, Sandoval E, Thielmann M, Jeppsson A, Landmesser U. 2017 EACTS Guidelines on perioperative medication in adult cardiac surgery. European Journal of Cardio-Thoracic Surgery. 2018;53(1):5-33.  https://doi.org/10.1093/ejcts/ezx314
  22. De Filippo O, Cortese M, Ascenzo F, Raposeiras-Roubin S, Abu-Assi E, Kinnaird T, Ariza-Solé A, Manzano-Fernández S, Templin C, Velicki L, Xanthopoulou I, Cerrato E, Rognoni A, Boccuzzi G, Montefusco A, Montabone A, Taha S, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Blanco P, Garay A, Quadri G, Varbella F, Queija B, Paz R, Fernández M, Pousa I, Gallo D, Morbiducci U, Dominguez-Rodriguez A, Valdés M, Cequier A, Alexopoulos D, Iñiguez-Romo A, Rinaldi M. Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry. American Journal of Cardiovascular Drugs. 2019;19(4):381-391.  https://doi.org/10.1007/s40256-019-00339-3
  23. Quadri G, D’Ascenzo F, Moretti C, D’Amico M, Raposeiras-Roubín S, Abu-Assi E, Henriques J, Saucedo J, González-Juanatey J, Wilton S, Kikkert W, Nuñez-Gil I, Ariza-Sole A, Song X, Alexopoulos D, Liebetrau C, Kawaji T, Huczek Z, Nie S, Fujii T, Correia L, Kawashiri M, García-Acuña J, Southern D, Alfonso E, Terol B, Garay A, Zhang D, Chen Y, Xanthopoulou I, Osman N, Möllmann H, Shiomi H, Omedè P, Montefusco A, Giordana F, Scarano S, Kowara M, Filipiak K, Wang X, Yan Y, Fan JY, Ikari Y, Nakahashi T, Sakata K, Yamagishi M, Kalpak O, Kedev S, Varbella F, Gaita F. Complete or incomplete coronary revascularisation in patients with myocardial infarction and multivessel disease: a propensity score analysis from the “real-life” BleeMACS (Bleeding complications in a Multicenter registry of patients discharged with diagnosis of Acute Coronary Syndrome) registry. EuroIntervention. 2017;13(4):407-414.  https://doi.org/10.4244/EIJ-D-16-00350
  24. Moscucci M, Fox K, Cannon C, Klein W, López-Sendón J, Montalescot G, White K, Goldberg R. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). European Heart Journal. 2003;24(20):1815-1823. https://doi.org/10.1016/s0195-668x(03)00485-8
  25. Marquis-Gravel G, Dalgaard F, Jones A, Lokhnygina Y, James S, Harrington R, Wallentin L, Steg P, Lopes R, Storey R, Goodman S, Mahaffey K, Tricoci P, White H, Armstrong P, Ohman E, Alexander J, Roe M. Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. Journal of the American College of Cardiology. 2020;76(2):162-171.  https://doi.org/10.1016/j.jacc.2020.05.031
  26. Wallentin L, Becker R, Budaj A, Cannon C, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey K, Scirica B, Skene A, Steg P, Storey R, Harrington R; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine. 2009;361(11):1045-1057. https://doi.org/10.1056/NEJMoa0904327
  27. Urban P, Mehran R, Colleran R, Angiolillo D, Byrne R, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson C, Gregson J, Haude M, James S, Kim H, Kimura T, Konishi A, Laschinger J, Leon M, Magee P, Mitsutake Y, Mylotte D, Pocock S, Price M, Rao S, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh R, Krucoff M, Morice M. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European Heart Journal. 2019;40:2632-2653. https://doi.org/10.1093/eurheartj/ehz372
  28. Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, Pilgrim T, Hong M, Kim H, Colombo A, Steg P, Zanchin T, Palmerini T, Wallentin L, Bhatt D, Stone G, Windecker S, Steyerberg E, Valgimigli M; PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389(10073):1025-1034. https://doi.org/10.1016/S0140-6736(17)30397-5
  29. Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, Hata Y, Yagi M, Suematsu N, Yokomatsu T, Takamisawa I, Doi M, Noda T, Okayama H, Seino Y, Tada T, Sakamoto H, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Hanaoka K, Morino Y, Kozuma K, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 Investigators. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA. 2019;321(24):2414-2427. https://doi.org/10.1001/jama.2019.8145
  30. Hahn J, Song Y, Oh J, Chun W, Park Y, Jang W, Im E, Jeong J, Cho B, Oh S, Yun K, Cho D, Lee J, Koh Y, Bae J, Choi J, Lee W, Yoon H, Lee S, Cho J, Choi W, Rha S, Lee J, Park T, Yang J, Choi J, Choi S, Lee S, Gwon H; SMART-CHOICE Investigators. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. JAMA. 2019;321(24):2428-2437. https://doi.org/10.1001/jama.2019.8146
  31. Valgimigli M, Frigoli E, Heg D, Tijssen J, Jüni P, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Tonino PAL, Roffi M, Lesiak M, Mahfoud F, Bartunek J, Hildick-Smith D, Colombo A, Stankovic G, Iñiguez A, Schultz C, Kornowski R, Ong P, Alasnag M, Rodriguez AE, Moschovitis A, Laanmets P, Donahue M, Leonardi S, Smits P; MASTER DAPT Investigators. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. The New England Journal of Medicine. 2021;385(18):1643-1655. https://doi.org/10.1056/NEJMoa2108749
  32. Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, Suwa S, Isawa T, Domei T, Yamaji K, Tatsushima S, Watanabe H, Ohya M, Tokuyama H, Tada T, Sakamoto H, Mori H, Suzuki H, Nishikura T, Wakabayashi K, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Morino Y, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 ACS Investigators. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. JAMA Cardiology. 2022;7(4):407-417.  https://doi.org/10.1001/jamacardio.2021.5244
  33. Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg P, Heg D, van Es G, McFadden E, Onuma Y, van Meijeren C, Chichareon P, Benit E, Möllmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns R, Huber K, Slagboom T, Serruys P, Windecker S; GLOBAL LEADERS Investigators. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392(10151):940-949.  https://doi.org/10.1016/S0140-6736(18)31858-0
  34. Notarangelo F, Maglietta G, Bevilacqua P, Cereda M, Merlini P, Villani G, Moruzzi P, Patrizi G, Malagoli Tagliazucchi G, Crocamo A, Guidorossi A, Pigazzani F, Nicosia E, Paoli G, Bianchessi M, Comelli M, Caminiti C, Ardissino D. Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes: The PHARMCLO Trial. Journal of the American College of Cardiology. 2018;71(17):1869-1877. https://doi.org/10.1016/j.jacc.2018.02.029
  35. Bergmeijer T, Janssen P, Schipper J, Qaderdan K, Ishak M, Ruitenbeek R, Asselbergs F, van ‘t Hof A, Dewilde W, Spanó F, Herrman J, Kelder J, Postma M, de Boer A, Deneer V, ten Berg J. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. American Heart Journal. 2014;168(1):16-22.e1.  https://doi.org/10.1016/j.ahj.2014.03.006
  36. Pereira N, Farkouh M, So D, Lennon R, Geller N, Mathew V, Bell M, Bae J, Jeong M, Chavez I, Gordon P, Abbott J, Cagin C, Baudhuin L, Fu Y, Goodman S, Hasan A, Iturriaga E, Lerman A, Sidhu M, Tanguay J, Wang L, Weinshilboum R, Welsh R, Rosenberg Y, Bailey K, Rihal C. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA. 2020;324(8):761-771.  https://doi.org/10.1001/jama.2020.12443
  37. Galli M, Benenati S, Franchi F, Rollini F, Capodanno D, Biondi-Zoccai G, Vescovo G, Cavallari L, Bikdeli B, Ten Berg J, Mehran R, Gibson C, Crea F, Pereira N, Sibbing D, Angiolillo D. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. European Heart Journal. 2022;43(10):959-967.  https://doi.org/10.1093/eurheartj/ehab836
  38. Cattaneo M. Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution? The Journal of Thrombosis and Haemostasis. 2012;10:327-336.  https://doi.org/10.1111/j.1538-7836.2011.04602.x
  39. Helten C, Naguib D, Dannenberg L, Pöhl M, Ayhan A, Hohlfeld T, Levkau B, Kelm M, Zeus T, Polzin A. Platelet function testing: dead or alive. The Journal of Thrombosis and Haemostasis. 2018;16(5):984-986.  https://doi.org/10.1111/jth.13997
  40. Kakouros N, Kickler TS, Laws KM, Rade JJ. Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness. The Journal of Thrombosis and Haemostasis. 2013;11(10):1814-1822. https://doi.org/10.1111/jth.12376
  41. Dobrovolsky AB, Laguta PS, Guskova EV, Yarovaya EB, Titaeva EV, Storozhilova AN, Panchenko EP. Effect of fibrinogen on platelet functional activity in VerifyNow test P2Y12. Biochemstry. 2016;81(5):439-444. (In Russ.). https://doi.org/10.1134/S0006297916050011
  42. Varenhorst C, Eriksson N, Johansson Å, Barratt B, Hagström E, Åkerblom A, Syvänen A, Becker R, James S, Katus H, Husted S, Steg P, Siegbahn A, Voora D, Teng R, Storey R, Wallentin L; PLATO Investigators. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. European Heart Journal. 2015;36(29):1901-1912. https://doi.org/10.1093/eurheartj/ehv116
  43. Pordzik J, Pisarz K, De Rosa S, Jones A, Eyileten C, Indolfi C, Malek L, Postula M. The Potential Role of Platelet-Related microRNAs in the Development of Cardiovascular Events in High-Risk Populations, Including Diabetic Patients: A Review. Frontiers in Endocrinology (Lausanne). 2018;9:74.  https://doi.org/10.3389/fendo.2018.00074
  44. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh B, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax J; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020;41(3):407-477.  https://doi.org/10.1093/eurheartj/ehz425
  45. Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt D, Bonello L, Collet J, Cuisset T, Franchi F, Gross L, Gurbel P, Jeong Y, Mehran R, Moliterno D, Neumann F, Pereira N, Price M, Sabatine M, So D, Stone G, Storey R, Tantry U, Trenk D, Valgimigli M, Waksman R, Angiolillo D. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions. 2019;12(16):1521-1537. https://doi.org/10.1016/j.jcin.2019.03.034
  46. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, De Hert S, de Laval I, Geisler T, Hinterbuchner L, Ibanez B, Lenarczyk R, Mansmann U, McGreavy P, Mueller C, Muneretto C, Niessner A, Potpara T, Ristić A, Sade LE, Schirmer H, Schüpke S, Sillesen H, Skulstad H, Torracca L, Tutarel O, Van Der Meer P, Wojakowski W, Zacharowski K; ESC Scientific Document Group, Knuuti J, Kristensen S, Aboyans V, Ahrens I, Antoniou S, Asteggiano R, Atar D, Baumbach A, Baumgartner H, Böhm M, Borger M, Bueno H, Čelutkienė J, Chieffo A, Cikes M, Darius H, Delgado V, Devereaux PJ, Duncker D, Falk V, Fauchier L, Habib G, Hasdai D, Huber K, Iung B, Jaarsma T, Konradi A, Koskinas KC, Kotecha D, Landmesser U, Lewis B, Linhart A, Løchen M, Maeng M, Manzo-Silberman S, Mindham R, Neubeck L, Nielsen J, Petersen SE, Prescott E, Rakisheva A, Saraste A, Sibbing D, Siller-Matula J, Sitges M, Stankovic I, Storey RF, Ten Berg J, Thielmann M, Touyz RM. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC). European Heart Journal. 2022;43(39):3826-3924. https://doi.org/10.1093/eurheartj/ehac270
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.